FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

4D Molecular Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$12.29+0.15 (+1.24%)

Close on Oct 19, 2026

Market cap: $863.64M
P/E (TTM): –
Dividend yield: –

4D Molecular Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	85	0.04	21	3.13	18	14	6.99
Research & Development	196	141	97	80	61	53	39
General & Administrative	49	47	36	33	28	17	14
Operating Expenses	245	188	134	113	89	70	58
Operating Income	-160	-188	-113	-110	-71	-57	-51
Interest & Investment Income	19	27	12	2.57	0.14	0.15	1.50
Other Non-Operating Income	19	27	12	2.54	0.02	-0.03	1.46
Asset Impairment Charges	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	–	–	–	–	0.00	-0.01
Income Tax Expense	0	0	0	0	0	0	–
Net Income incl. Noncontrolling Interests	-140	-161	-101	-107	-71	-57	-49
Net Income	-140	-161	-101	-107	-71	-57	-49
Net Income to Common	-140	-161	-101	-107	-71	-57	-49
EPS (Basic)(per share)	-2.42	-2.98	-2.58	-3.32	-2.57	-8.82	-9.59
EPS (Diluted)(per share)	-2.42	-2.98	-2.58	-3.32	-2.57	-8.82	-9.59
Shares Outstanding (Basic, Weighted)(shares)	58	54	39	32	28	6.43	5.14
Shares Outstanding (Diluted, Weighted)(shares)	58	54	39	32	28	6.43	5.14
EBITDA	-155	-183	-109	-108	-70	-55	-50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -214.2%
Net margin: -194.7%
Return on equity, FY2025: -27.6%

Financial strength

Current ratio: 8.03
Debt to equity: 0.05
Debt to assets: 4.0%
Cash to current liabilities: 147.6%

Valuation

P/E ratio: –
Price to sales: 9.39
Price to book: 2.12
Dividend yield: –